Investors & Media

  • Webcast
    15th Annual Morgan Stanley Global Healthcare Conference
    09/13/17 2:10 pm EDT

Company Profile

We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.

Recent Press Releases

More >>
Date Title and Summary
Toggle Summary Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
Toggle Summary New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
29% Objective Response Rate and 57% Disease Control Rate in Combination with Immune Checkpoint Inhibitor Treatment in Patients with Head and Neck Cancer Four Complete Responses and Four Partial Responses Observed in 28-patient Study CARLSBAD, Calif. , Sept.
Toggle Summary Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA
<p>CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today
Toggle Summary Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
CARLSBAD, Calif. , Aug. 30, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $40 million milestone payment from Biogen associated with the pricing approval of SPINRAZA ® (nusinersen) in Japan . SPINRAZA was approved for individuals with

Upcoming Events

More >>
There are currently no events to display.

For more information requests, please visit our Information Request page.

If you are interested in Ionis Pharmaceuticals’ investment details,
please visit our Investor FAQ page.

Copyright Nasdaq. Minimum 15 minutes delayed.